Article
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Cancer research - 1 Dec 2003
Bakkar Ashraf A, Wallerand Herve, Radvanyi François, Lahaye Jean-Baptiste, Pissard Serge, Lecerf Laure, Kouyoumdjian Jean Claude, Abbou Claude C, Pairon Jean-Claude, Jaurand Marie-Claude, Thiery Jean-Paul, Chopin Dominique K, de Medina Sixtina Gil Diez
Abstract excerpt
FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liquid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.